Zai Lab Limited American Depositary Shares ZLAB
i
Market dataready · fetched 2026-11-13T00:47:04.269Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T23:17:31.585600199Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T00:47:03.793004+00:00
Zai Lab Limited American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 21.11 | 227.0% | 24.1% | |||
| 25Δ | 21.89 | 260.2% | 23.5% | |||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 28.15 | 139.9% | 14.1% | |||
| 45Δ | 27.42 | 140.6% | 12.3% | |||
| 50Δ | 26.69 | 141.4% | 10.6% | |||
| 55Δ | 25.96 | 142.1% | 8.8% | |||
| 60Δ | 25.23 | 142.9% | 7.1% | |||
| 65Δ | 24.54 | 141.2% | 5.8% | |||
| 70Δ | 23.85 | 138.3% | 4.7% | |||
| 75Δ | 23.17 | 135.4% | 3.6% | |||
| 80Δ | 22.48 | 132.6% | 2.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.11
- IV
- 227.0%
- B/E move
- 24.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.89
- IV
- 260.2%
- B/E move
- 23.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 28.15
- IV
- 139.9%
- B/E move
- 14.1%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 27.42
- IV
- 140.6%
- B/E move
- 12.3%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 26.69
- IV
- 141.4%
- B/E move
- 10.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 25.96
- IV
- 142.1%
- B/E move
- 8.8%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 25.23
- IV
- 142.9%
- B/E move
- 7.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 24.54
- IV
- 141.2%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 23.85
- IV
- 138.3%
- B/E move
- 4.7%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 23.17
- IV
- 135.4%
- B/E move
- 3.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 22.48
- IV
- 132.6%
- B/E move
- 2.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 68.95% | |
| 74.72% | |
| 75.98% | |
| 80.97% | |
| 68.57% | |
| 64.46% | |
| 73.79% | |
| 78.92% | |
| 70.52% | |
| 79.63% |
Biotechnology
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
Description unavailable
More →